Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Edward Dela Cruz Drilon, Natasha Rekhtman, Maria E. Arcila et al. · The Lancet Oncology · 2016
Cited by 484 works. doi:10.1016/s1470-2045(16)30562-9
Authors
- Alexander Edward Dela Cruz Drilon
- Natasha Rekhtman
- Maria E. Arcila
- Lu Wang
- Ai Ni
- Melanie Albano
- Martine van Voorthuysen
- Romel Somwar
- Roger S. Smith
- Joseph Montecalvo
- Andrew J. Plodkowski
- Michelle S. Ginsberg
- Gregory J. Riely
- Charles M. Rudin
- Marc Ladanyi
- Mark G. Kris
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Optimal two-stage designs for phase II clinical trials
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- RET, ROS1 and ALK fusions in lung cancer